Exagen Inc. (XGN)
| Market Cap | 178.13M |
| Revenue (ttm) | 48.28M |
| Net Income (ttm) | -23.25M |
| Shares Out | 16.16M |
| EPS (ttm) | -1.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,038 |
| Open | 12.20 |
| Previous Close | 11.81 |
| Day's Range | 10.51 - 11.78 |
| 52-Week Range | 10.13 - 24.67 |
| Beta | 0.42 |
| Analysts | Strong Buy |
| Price Target | 24.40 (+121.4%) |
| Earnings Date | Nov 10, 2021 |
About XGN
Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with o...
Financial Performance
In 2020, Exagen's revenue was $41.98 million, an increase of 3.93% compared to the previous year's $40.39 million. Losses were -$16.69 million, 38.6% more than in 2019.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Exagen stock is "Strong Buy." The 12-month stock price forecast is 24.40, which is an increase of 121.42% from the latest price.
News
Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Piper Sandler 33rd Annual Virtual Hea...
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) delivered earnings and revenue surprises of 2.33% and 0.97%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Exagen: Q3 Earnings Insights
Exagen (NASDAQ:XGN) reported its Q3 earnings results on Wednesday, November 10, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
Earnings Preview: Exagen Inc. (XGN) Q3 Earnings Expected to Decline
Exagen Inc. (XGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More Accurate Diagnostic Testing w...
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE Lupus are a contracted covered servi...
Exagen Inc. Announces $27.2 Million Debt Refinancing
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security agr...
Exagen Inc. to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Cantor Fitzgerald Virtual Global Hea...
Exagen Stock Gains As Q2 Financials Surpass Street Expectations
Exagen Inc (NASDAQ: XGN) shares are moving after the Company's Q2 2021 revenue increased 43% Y/Y to $12.8 million due to increased testing volumes, beating the consensus of $11.48 million. Its flagship ...
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) delivered earnings and revenue surprises of 24.00% and 9.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Exagen: Q2 Earnings Insights
Shares of Exagen (NASDAQ:XGN) fell after the company reported Q2 results. Quarterly Results Earnings per share were down 40.74% over the past year to ($0.38), which beat the estimate of ($0.44).
Exagen Inc. Reports Second Quarter 2021 Results
Quarterly Records: Total Revenue, AVISE® CTD Revenue and Volumes, Ordering Healthcare Providers and Adopters Quarterly Records: Total Revenue, AVISE® CTD Revenue and Volumes, Ordering Healthcare Provide...
Exagen Appoints Ana Hooker to Board of Directors
SAN DIEGO, July 30, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the addition of Ms. Ana Hooker as an additional independe...
Exagen Inc. to Participate in the Canaccord Genuity 41st Annual Growth Conference
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 41st Annual Growth ...
Exagen to Announce Second Quarter 2021 Financial Results on August 9, 2021
SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2021 after the m...
Earnings Preview: Exagen Inc. (XGN) Q2 Earnings Expected to Decline
Exagen Inc. (XGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVISE® Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving a Definitive SLE Diagnosis and...
SAN DIEGO, July 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the publication of their latest clinical utility study in Lupu...
Exagen Elects Frank Stokes to Board of Directors
SAN DIEGO, June 18, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the company's stockholders approved the election of Mr. F...
Exagen Inc. to Participate in the William Blair 41st Annual Growth Stock Conference
SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 41st Annual Growth Stock...
Exagen Inc. Reports First Quarter 2021 Results
Quarterly Records: AVISE® CTD Volumes, Ordering Healthcare Providers and Adopters
Exagen Inc., Allegheny Health Network Research Institute and AHN Autoimmunity Institute Announce Collaboration to Dev...
The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases The suite of innovative biomarker assays seeks to...
Earnings Preview: Exagen Inc. (XGN) Q1 Earnings Expected to Decline
Exagen Inc. (XGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exagen Announces New Campaign and Initiatives for Lupus Awareness Month
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awarene...
Exagen to Announce First Quarter 2021 Financial Results on May 11, 2021
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after the...
Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today tha...
Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to ...
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten publ...